Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial
Chimeric Therapeutics (ASX:CHM) has reported one leukaemia patient has shown a complete response in its latest drug trial.
OZF
0.39%
$20.52
SPDR S&P/ASX 200 FINANCIALS EX A-REIT FUND - Corporate Spotlight
Currently unlisted.
Add to my watchlist
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
No Corporate Spotlight currently available.